Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression

Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression

Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, a...

Full description

Bibliographic Details
Main Authors: Hyun-Sun Park, Jongmin Kim, Seong Hoon Ahn, Hong-Yeoul Ryu
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
histone deacetylase (HDAC)
depression
biomarker
anti-depressant therapy
Online Access:https://www.mdpi.com/1422-0067/22/10/5398
id doaj-051e96af1a4345eaa163d6fcc88e51c8
record_format Article
spelling doaj-051e96af1a4345eaa163d6fcc88e51c82021-06-01T00:38:34ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-01225398539810.3390/ijms22105398Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of DepressionHyun-Sun Park0Jongmin Kim1Seong Hoon Ahn2Hong-Yeoul Ryu3Department of Biochemistry, Inje University College of Medicine, Busan 47392, KoreaDivision of Biological Sciences, Sookmyung Women’s University, Seoul 04310, KoreaDepartment of Molecular and Life Science, College of Science and Convergence Technology, Hanyang University ERICA Campus, Ansan 15588, KoreaBK21 FOUR KNU Creative BioResearch Group, School of Life Sciences, College of National Sciences, Kyungpook National University, Daegu 41566, KoreaDepression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC inhibitors.https://www.mdpi.com/1422-0067/22/10/5398histone deacetylase (HDAC)depressionbiomarkeranti-depressant therapy
collection DOAJ
language English
format Article
sources DOAJ
author Hyun-Sun Park
Jongmin Kim
Seong Hoon Ahn
Hong-Yeoul Ryu
spellingShingle Hyun-Sun Park
Jongmin Kim
Seong Hoon Ahn
Hong-Yeoul Ryu
Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
International Journal of Molecular Sciences
histone deacetylase (HDAC)
depression
biomarker
anti-depressant therapy
author_facet Hyun-Sun Park
Jongmin Kim
Seong Hoon Ahn
Hong-Yeoul Ryu
author_sort Hyun-Sun Park
title Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
title_short Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
title_full Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
title_fullStr Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
title_full_unstemmed Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
title_sort epigenetic targeting of histone deacetylases in diagnostics and treatment of depression
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-05-01
description Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC inhibitors.
topic histone deacetylase (HDAC)
depression
biomarker
anti-depressant therapy
url https://www.mdpi.com/1422-0067/22/10/5398
work_keys_str_mv AT hyunsunpark epigenetictargetingofhistonedeacetylasesindiagnosticsandtreatmentofdepression
AT jongminkim epigenetictargetingofhistonedeacetylasesindiagnosticsandtreatmentofdepression
AT seonghoonahn epigenetictargetingofhistonedeacetylasesindiagnosticsandtreatmentofdepression
AT hongyeoulryu epigenetictargetingofhistonedeacetylasesindiagnosticsandtreatmentofdepression
_version_ 1721414194259034112

Similar Items